Navigation Links
NephroGenex Announces Full Enrollment in New Pyridorin(TM) Clinical Trial - PYR 210
Date:9/9/2009

PRINCETON, N.J., Sept. 9 /PRNewswire/ -- NephroGenex, Inc., a privately held drug development company focusing on kidney disease, today announced the completion of patient enrollment in its Phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin(TM) (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been randomized.

The study is being conducted by the Collaborative Study Group (CSG) at approximately 65 sites in the United States, Australia and Israel. The CSG is a site management organization of nephrologists that has conducted notable landmark studies in diabetic nephropathy in the past, including studies leading to approval of drugs for this indication.

The trial is evaluating two doses of Pyridorin(TM) against placebo in approximately 300 patients for a one year treatment period. Recruited type 2 diabetic patients have elevated serum creatinine levels and significant proteinuria. The estimated study completion date is August 2010. Further details of PYR-210 are available at clinicaltrials.gov (Identifier NCT00734253). The trial is incorporating the latest discussion with the FDA regarding the use of an approvable surrogate endpoint that would be subsequently confirmed with hard clinical endpoints.

In previous Phase 2a trials, Pyridorin(TM) therapy demonstrated a significant treatment effect in slowing the progression of diabetic nephropathy as measured by the change in serum creatinine and serum cystatin C over six months, as well as a reduction in urine TGF-beta.

Diabetic kidney disease afflicts about 20% of all diabetics and is the major cause of end-stage renal disease (ESRD) which is an enormous drain on healthcare expenditures. Mortality rates of ESRD patients can reach 20% annually. Pyridorin(TM) has been awarded Fast Track status by the FDA due to the unmet medical need of this life-threatening disease.

About NephroGenex, Inc.

NephroGenex (www.nephrogenex.com) is a drug development company focusing on kidney disease. More than 20 million Americans have some form of chronic kidney disease, and over 400,000 in the US have end stage renal disease requiring dialysis, making renal disease one of the costliest illnesses to treat. The Company is developing Pyridorin(TM) (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease. Pyridorin(TM) has demonstrated a significant treatment effect in slowing the progression of diabetic nephropathy in two Phase IIa clinical trials, and has been awarded Fast Track status by the FDA. Pyridorin(TM) is one of only a few drug candidates in advanced clinical trials for diabetic kidney disease, and possesses a distinctly new mechanism of action over currently approved treatments. NephroGenex will seek a partner for Phase III development and commercialization.

    Contact:
    J. Wesley Fox, Ph.D.
    President and CEO
    NephroGenex, Inc.
    (609) 986-1780 phone
    (609) 275-5610 fax
    www.nephrogenex.com
    Email: fox@nephrogenex.com

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com


'/>"/>
SOURCE NephroGenex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... scientific laboratories. The assembly protocols involve many repetitive steps and often scientists require ... which enables the high-throughput needed, and results in a lower error rate and ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who ... at Intercontinental Time Square, New York. , The program will be led ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education ... quality, the field must first improve teacher preparation program design. It then asserts ... and that decades of input- and outcome-based research has failed to improve teacher ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield Advisors ... brings his extensive knowledge of appraisals, property values, ad valorem taxation, and government ... valuation industry for more than 40 years. , “Ruel is a great addition ...
(Date:3/28/2017)... ... 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid ... Thyroid Secret. Dr. Wentz talked about journey and research recently on a blog and ... NOT the only solution to deal with thyroid disease. , Dr. Wentz completed ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Mar 29, 2017 Research and Markets has ... Forecast to 2023" report to their offering. ... The ablation device global market ... $20,995.5 million by 2023. Ablation is the minimally ... purposes, from cancerous or diseased tissue removal, to the removal of ...
(Date:3/29/2017)... , March 29, 2017   Dynatronics ... today the appointment of Cynthia L. McHenry ... will be responsible for leading Dynatronics manufacturing, distribution, ... will report to Dynatronics, CEO Kelvyn H. ... concludes an extensive search process conducted by the ...
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... Data published in a research report by Grand View Research, ... of USD 55.8 billion by 2025. The projection takes into consideration the ... and a more open approach towards cannabis products around the world. In ... , North Dakota , Ohio , ...
Breaking Medicine Technology: